Today: 29 June 2026
NAB share price jumps again to a fresh record after Q1 update — what investors watch next
19 February 2026
1 min read

NAB share price jumps again to a fresh record after Q1 update — what investors watch next

Sydney, February 19, 2026, 16:55 (AEDT) — Action shifting to post-market trades.

  • National Australia Bank shares climbed again, closing at a fresh record for the second session running
  • The rally sprang to life after NAB’s first-quarter trading update landed. Some brokers didn’t wait long to chime in.
  • The focus now turns to capital, margins, and when the bank plans to release its May results.

National Australia Bank Ltd stock notched a fresh record during Thursday’s session, peaking at A$48.68 before closing up 2.4% at A$48.28. The move extends a 4.0% rally from the day before, as investors continued to respond to the company’s latest update.

Investors now face their first real test of appetite for bank risk since February’s reporting rush, a stretch when even small shifts in capital or margins unsettled the mood. NAB put out its update with the shares trading near recent peaks — which didn’t leave much room for error.

Traders are watching to see whether the momentum from this quarter turns into earnings upgrades—or if the bank’s capital buffer ends up getting in the way. Competition among lenders for deposits and home loans is fierce, usually showing up early in funding costs and pricing.

NAB posted a 15% rise in “cash earnings” from the prior half’s average, the bank’s preferred profit measure. Underlying profit moved up 12%. Revenue gained 6%. Costs held steady. Net interest margin edged up 2 basis points to 1.80%, while the CET1 ratio eased to 11.48%. “We have started FY26 strongly,” said chief executive Andrew Irvine. NAB

The quarter brought a A$170 million credit impairment charge for the bank, but non-performing exposures edged down to 1.47% of gross loans and acceptances. Management pointed to gains, citing stronger numbers in business lending and the Australian mortgage book.

Analysts found cause for optimism. UBS’s Jon Storey pointed to strong initial figures, suggesting they “could trigger an earnings upgrade.” At JPMorgan, Angus Triggs described the capital drop as “no worse than feared,” and highlighted better credit quality. Capital Brief

Still, that capital line looms—the stock’s glaring “but.” Should risk-weighted assets keep ticking up, or if mortgage rivalry starts biting into pricing, investors might soon wonder just what returns the bank can really hand over to shareholders—and how long that’ll take.

Another wrinkle: that clean credit story could unravel. NAB flagged that individual charges mainly cropped up in Australian business loans and unsecured retail—two areas with a reputation for turning south quickly when conditions worsen.

Broker updates are in focus as investors look for any momentum cues, trying to figure out if shares can stick to those record levels by Friday. Bank stocks, well known for their habit of snapping back after fast climbs, keep things unpredictable.

NAB will release its half-year results on May 4, as outlined in the bank’s financial calendar. The interim dividend hits its ex-dividend date on May 7, followed by the record date on May 8.

Shan Ahmed Khan is a senior markets reporter at TS2.tech, specializing in stocks, technology and macroeconomic trends. A graduate of the Lahore University of Management Sciences (LUMS), he previously worked in investment research and market analysis. His coverage helps readers understand the key developments influencing global financial markets and emerging industries.

Stock Market Today

  • Neurocrine Biosciences (NBIX) Gains as Strong Earnings Forecasts Boost Stock
    June 29, 2026, 5:49 AM EDT. Neurocrine Biosciences (NBIX) has emerged as a robust biotech performer with strong earnings momentum driven by its flagship treatment INGREZZA, which treats movement disorders. Analysts have sharply raised earnings per share (EPS) estimates for NBIX across upcoming quarters and fiscal years, reflecting increased confidence in the stock. INGREZZA's sales reached $2.86 billion in 2025, up 22% year-over-year, with projected growth continuing in 2026. The company also benefits from growing physician adoption and expanding patient awareness. Rising earnings forecasts, driven by strong operational performance and a broad consensus among analysts, have elevated NBIX to a Zacks Rank #1 (Strong Buy). Investors see Neurocrine's expanding portfolio and pipeline as key to sustaining growth beyond INGREZZA's success.

Latest articles

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

ServiceNow (NYSE:NOW) stock: $9 billion Friday jump puts contract base back in focus

29 June 2026
ServiceNow (NYSE:NOW) surged 9.85% to $98.34 Friday, adding $9.1 billion in equity value—about 72% of its $12.64 billion Q1 current remaining performance obligations—as software stocks outperformed amid rotation out of AI names; the move comes ahead of a potential near-term bookings catalyst tied to price increases and legacy tier retirements, with short interest at 5.82% of float.
Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

Nvidia holds $47 billion-per-point sway as Nasdaq tries for bounce

29 June 2026
Nvidia’s $4.7 trillion market value means every 1% stock move shifts $47 billion, putting massive index risk in focus as AI capex spending faces fresh scrutiny from new BIS data and rising China chip competition, with premarket gains tested by funding and substitution risks.
Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe
Previous Story

Uber stock: Tuesday test looms after Uber Eats targets $1 billion boost in Europe

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares
Next Story

Johnson & Johnson stock falls on DePuy sale talk — what to watch next for JNJ shares

Go toTop